Cellectis SA (CLLS) has released an update.
Cellectis S.A., a company operating in the biotechnology sector, has released its unaudited interim condensed consolidated financial statements for the first half of 2024, prepared in accordance with International Accounting Standard 34. The report is presented in U.S. dollars and includes forward-looking statements subject to various risks and uncertainties that could significantly affect actual results. The company emphasizes that these statements are not guarantees of future performance and that outcomes may differ materially due to numerous factors.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
